神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

休市中 04-26 16:00:00 EDT

135.99

-1.77

-1.28%

盘后135.99

+0.000.00%

17:10 EDT

最高138.63	最低135.17	成交量71.76万
今开137.47	昨收137.76	日振幅2.51%
总市值136.78亿	流通市值135.11亿	总股本1.01亿
成交额9,777万	换手率0.72%	流通股本9,935万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":135.99,"timestamp":1714161600000,"preClose":137.76,"halted":0,"volume":717575,"hourTrading":{"tag":"盘后","latestPrice":135.99,"preClose":135.99,"latestTime":"17:10 EDT","volume":18507,"amount":2516816.56,"timestamp":1714165826192},"delay":0,"floatShares":99353978,"shares":100580497,"eps":2.47,"marketStatus":"休市中","marketStatusCode":7,"change":-1.77,"latestTime":"04-26 16:00:00 EDT","open":137.47,"high":138.63,"low":135.17,"amount":97773698.279,"amplitude":0.025116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.47,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714377600000},"adr":0,"listingDate":832824000000,"adjPreClose":137.76,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":135.01,"preClose":137.76,"latestTime":"07:52 EDT","volume":7,"amount":956.79997,"timestamp":1714132358270},"postHourTrading":{"tag":"盘后","latestPrice":135.99,"preClose":135.99,"latestTime":"17:10 EDT","volume":18507,"amount":2516816.56,"timestamp":1714165826192},"volumeRatio":0.8148535176406094},"requestUrl":"/m/hq/s/NBIX/wiki","defaultTab":"wiki","newsList":[{"id":"2429438171","title":"Neurocrine Biosciences(NBIX.US)潜在“first-in-class”小分子疗法达到2期临床终点 显著缓解抑郁症状","url":"https://stock-news.laohu8.com/highlight/detail?id=2429438171","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429438171?lang=zh_cn&edition=full","pubTime":"2024-04-24 10:31","pubTimestamp":1713925868,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Neurocrine Biosciences(NBIX.US)宣布，在研疗法NBI-1065845在治疗抑郁症(MDD)成年患者的2期临床试验SAVITRI中获得积极顶线数据。NBI-1065845是一款潜在“first-in-class”的AMPA受体正向别构调节剂(PAM)，旨在治疗在抑郁发作中至少对一种抗抑郁药没有应答的MDD患者。NBI-1065845的耐受性总体良好，头痛是最常见的不良事件。两个剂量的不良事件情况与安慰剂组相当。研究中未报告死亡或严重不良事件，整个研究期间的中止率保持低水平。SAVITRI研究的更多数据将在未来的科学会议上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108233.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429907251","title":"神经分泌生物科学盘中异动 早盘快速拉升8.16%报144.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429907251","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429907251?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:32","pubTimestamp":1713879137,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日21时32分，神经分泌生物科学股票出现波动，股价快速拉升8.16%。截至发稿，该股报144.57美元/股，成交量13.2855万股，换手率0.13%，振幅3.49%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.81%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。消息层面，截至21时32分，《Needham：重申Neurocrine Biosciences持有评级。》资讯为影响神经分泌生物科学的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042321321787a65b1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042321321787a65b1e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429192203","title":"BUZZ-Neurocrine 因抑郁症治疗在中期试验中取得成功而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2429192203","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429192203?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:17","pubTimestamp":1713878254,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月23日 - ** Neurocrine Biosciences   股价盘前上涨约5.9%至141.50美元** 该公司称 (link)，其口服药物NBI-1065845在一项评估重度抑郁症患者的中期试验中达到了主要目标 ** 该公司称，该药物在统计学上显著降低了一种抑郁评分量表的总分 ** 公司期待与美国 FDA 会面，讨论该疗法的后期研究** 截至上次收盘，该公司股价年累计上涨了1.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428232112","title":"Wedbush：重申Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价147.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428232112","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428232112?lang=zh_cn&edition=full","pubTime":"2024-04-18 01:25","pubTimestamp":1713374703,"startTime":"0","endTime":"0","summary":"Wedbush：重申Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价147.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418012505878b2263&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418012505878b2263&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422915817","title":"神经分泌生物科学盘中异动 股价大跌5.37%报133.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422915817","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422915817?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:11","pubTimestamp":1711548673,"startTime":"0","endTime":"0","summary":"北京时间2024年03月27日22时11分，神经分泌生物科学股票出现异动，股价大幅跳水5.37%。截至发稿，该股报133.58美元/股，成交量16.4162万股，换手率0.16%，振幅5.30%。最近的财报数据显示，该股实现营业收入18.87亿美元，净利润2.50亿美元，每股收益2.56美元，毛利18.30亿美元，市盈率54.53倍。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.05%。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722111487e7c4f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722111487e7c4f5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421904174","title":"神经分泌生物科学盘中异动 股价大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421904174","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421904174?lang=zh_cn&edition=full","pubTime":"2024-03-21 21:56","pubTimestamp":1711029363,"startTime":"0","endTime":"0","summary":"北京时间2024年03月21日21时56分，神经分泌生物科学股票出现波动，股价急速拉升5.13%。截至发稿，该股报147.86美元/股，成交量46.4254万股，换手率0.47%，振幅5.86%。其相关个股中，大自然药业、神经分泌生物科学、Mira Pharmaceuticals, Inc.涨幅较大，Petros Pharmaceuticals, Inc.、Agile Therapeutics, Inc.、Rockwell Medical, Inc.较为活跃，换手率分别为6.31%、4.31%、3.10%，振幅较大的相关个股有Clever Leaves Holdings Inc C/Wts 18/12/2025、Rockwell Medical, Inc.、Incannex Healthcare Inc.，振幅分别为40.00%、10.30%、10.26%。消息层面，截至21时56分，神经分泌生物科学股票正面舆情新闻比例100%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032121560387e7aba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032121560387e7aba8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413273894","title":"美国研究综述-Biomarin Pharmaceutical、Intuit、Penumbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2413273894","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413273894?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:28","pubTimestamp":1708673314,"startTime":"0","endTime":"0","summary":"    路透社2月23日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Biomarin Pharmaceutical、Intuit 和 Penumbra。要闻             * Biomarin Pharmaceutical Inc   ：Piper Sandler将目标价从115美元下调至107美元             * Intuit Inc   ：Susquehanna将目标价从700美元上调至775美元             * Penumbra Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2410570280","title":"神经分泌生物科学2023财年实现净利润2.50亿美元，同比增加61.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2410570280","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2410570280?lang=zh_cn&edition=full","pubTime":"2024-02-10 00:24","pubTimestamp":1707495874,"startTime":"0","endTime":"0","summary":"12月31日，神经分泌生物科学公布财报，公告显示公司2023财年净利润为2.50亿美元，同比增加61.29%；其中营业收入为18.87亿美元，同比增加26.73%，每股基本收益为2.56美元。从资产负债表来看，神经分泌生物科学总负债10.19亿美元，其中短期债务1.70亿美元，资产负债比为3.20，流动比率为2.46。机构评级：截至2023年12月31日，当前有26家机构对神经分泌生物科学目标价做出预测，其中目标均价为148.99美元，其中最低目标价为106.00美元，最高目标价为170.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021000243587819d79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024021000243587819d79&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2409253442","title":"Neurocrine Biosciences Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2409253442","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409253442?lang=zh_cn&edition=full","pubTime":"2024-02-07 21:01","pubTimestamp":1707310893,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc    公布的截至 12 月的季度调整后每股收益为 1.44 美元，高于去年同期的每股收益 88 美分。* 营收同比增长 25%，达到 5.152 亿美元；分析师预期为 5.1847 亿美元。* Neurocrine Biosciences 公司公布的本季度每股收益为 1.44 美元。* 公司报告的季度净收入为 1.477 亿美元。* Neurocrine Biosciences Inc 的股价本季度上涨了 8.5%。2月7日 - 预测变化   * 在过去三个月中，分析师的平均盈利预测上升了约 2.9%。华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 150.00 美元。本摘要由 LSEG 2 月 7 日 01:01 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409483493","title":"Neurocrine Biosciences Inc    预计每股收益 1.15 美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2409483493","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409483493?lang=zh_cn&edition=full","pubTime":"2024-02-05 20:03","pubTimestamp":1707134607,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences公司   将于2月7日公布截至2023年12月31日的财报，预计该公司的季度收入将有所增长。   * LSEG 分析师对 Neurocrine Biosciences 公司的平均预期为每股收益 1.15 美元。* 华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 150.00 美元，高于其最新收盘价 141.74 美元。2月5日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393460490","title":"神经分泌生物科学盘中异动 早盘股价大涨5.03%报127.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2393460490","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2393460490?lang=zh_cn&edition=full","pubTime":"2023-12-22 22:35","pubTimestamp":1703255710,"startTime":"0","endTime":"0","summary":"北京时间2023年12月22日22时35分，神经分泌生物科学股票出现异动，股价急速上涨5.03%。截至发稿，该股报127.25美元/股，成交量13.0613万股，换手率0.13%，振幅3.40%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.23%。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312222235107903147b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202312222235107903147b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2392063138","title":"百奥赛图-B(02315.HK)与Neurocrine Biosciences达成多靶点抗体协定","url":"https://stock-news.laohu8.com/highlight/detail?id=2392063138","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2392063138?lang=zh_cn&edition=full","pubTime":"2023-12-20 07:44","pubTimestamp":1703029447,"startTime":"0","endTime":"0","summary":"格隆汇12月20日丨百奥赛图-B发布公告，与Neurocrine Biosciences, Inc.达成一项抗体评估与选择权协定。该协定将许可Neurocrine Biosciences获得百奥赛图针对多个特定靶点的全人抗体，并有权获得针对选定抗体进行治疗性产品的开发、生产和商业化的全球任意使用权益。此次授权的抗体由百奥赛图专有的RenMice平台产生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122007460182631c78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023122007460182631c78&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2391169949","title":"韦德布什：2024年买这些生物科技股吧","url":"https://stock-news.laohu8.com/highlight/detail?id=2391169949","media":"新浪财经","top":-1,"share":"https://www.laohu8.com/m/news/2391169949?lang=zh_cn&edition=full","pubTime":"2023-12-15 22:46","pubTimestamp":1702651602,"startTime":"0","endTime":"0","summary":"进入2024年，韦德布什认为生物技术行业早该恢复正增长了，特别是在中小型股。韦德布什在2024年的热门选择包括Ascendis Pharma、Neurocrine Biosciences和Sarepta Therapeutics。韦德布什认为，生物技术在10月份达到了最低点，随着更多的成功项目，该行业在2024年内可能会走高。韦德布什指出，尽管2023年给生物技术投资者带来了许多挑战，但估值过高并不是其中之一，资本市场仍然对生物技术公司开放。韦德布什继续认为，到2024年，这种情况将继续存在。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023121522491583fc9125&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2381009155","title":"神经分泌生物科学2023财年第三财季实现净利润83.10百万美元，同比增加21.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2381009155","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2381009155?lang=zh_cn&edition=full","pubTime":"2023-11-05 00:25","pubTimestamp":1699115156,"startTime":"0","endTime":"0","summary":"9月30日，神经分泌生物科学公布财报，公告显示公司2023财年第三财季净利润为83.10百万美元，同比增加21.31%；其中营业收入为4.99亿美元，同比增加28.61%，每股基本收益为0.85美元。从资产负债表来看，神经分泌生物科学总负债8.46亿美元，其中短期债务1.88亿美元，资产负债比为3.37，流动比率为2.39。机构评级：截至2023年9月30日，当前有25家机构对神经分泌生物科学目标价做出预测，其中目标均价为136.80美元，其中最低目标价为100.00美元，最高目标价为170.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110500260383e967e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023110500260383e967e6&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0302},{"period":"1month","weight":-0.0133},{"period":"3month","weight":-0.0433},{"period":"6month","weight":0.2821},{"period":"1year","weight":0.3345},{"period":"ytd","weight":0.0321}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，目的很简单：为有巨大需求的人减轻痛苦，但选择很少。三十年来，该公司运用对神经科学以及大脑和身体系统之间相互联系的独特见解，推进用于治疗未得到充分解决的神经、神经内分泌和神经精神疾病的药物，他们将继续不懈地追求药物，以减轻令人衰弱的疾病和紊乱的负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.066296},{"month":2,"riseRate":0.321429,"avgChangeRate":-0.00768},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.006842},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.012465},{"month":5,"riseRate":0.592593,"avgChangeRate":0.047818},{"month":6,"riseRate":0.5,"avgChangeRate":0.019514},{"month":7,"riseRate":0.464286,"avgChangeRate":-0.003857},{"month":8,"riseRate":0.535714,"avgChangeRate":0.024904},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032175},{"month":10,"riseRate":0.535714,"avgChangeRate":0.029555},{"month":11,"riseRate":0.571429,"avgChangeRate":0.038168},{"month":12,"riseRate":0.642857,"avgChangeRate":0.042544}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}